Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04507503 |
Expanded Access Status :
Approved for marketing
First Posted : August 11, 2020
Last Update Posted : February 23, 2024
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Advanced Cholangiocarcinoma | Drug: TAS-120 |
Study Type : | Expanded Access |
Expanded Access Type : | Treatment IND/Protocol |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
- Drug: TAS-120
Futibatinib 20mg QD orally on a 28 days cycleOther Name: Futibatinib
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Provide written informed consent.
- >18 years of age.
- Histologically confirmed, locally advanced, or metastatic, or recurrent unresectable CCA harboring FGFR2 gene rearrangements based on testing performed by a qualified (CLIA-certified) laboratory.
- Patient has failed standard therapy or standard therapy is not tolerated.
- Has measurable or non-measurable lesion(s).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Adequate organ function.
Exclusion Criteria:
- History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis.
- History and/or current evidence of clinically significant ectopic mineralization/calcification.
- History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination.
- A serious illness or medical condition(s)
- Pregnant or breast-feeding female
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04507503
United States, Arizona | |
Banner MD Anderson | |
Gilbert, Arizona, United States, 85234 | |
United States, California | |
University of California, San Francisco (UCSF) | |
San Francisco, California, United States, 94143 | |
UCLA Division of Hematology-Oncology | |
Santa Monica, California, United States, 90404 | |
United States, Florida | |
Mount Sinai Center of Florida | |
Miami Beach, Florida, United States, 33140 | |
Advent Health Orlando | |
Orlando, Florida, United States, 32804 | |
United States, Illinois | |
University of Chicago | |
Chicago, Illinois, United States, 60637 | |
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Baltimore, Maryland, United States, 21231 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, Missouri | |
University of Kansas Cancer Center | |
Lee's Summit, Missouri, United States, 64064 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Oregon | |
Providence Portland Medical Center | |
Portland, Oregon, United States, 97213 | |
United States, Texas | |
MD Anderson | |
Houston, Texas, United States, 77030 | |
United States, Utah | |
Utah Cancer Specialists | |
Salt Lake City, Utah, United States, 84106 | |
United States, Washington | |
Seattle Cancer Care Alliance | |
Seattle, Washington, United States, 98109 | |
United States, Wisconsin | |
Aurora Cancer care | |
Grafton, Wisconsin, United States, 53024 |
Responsible Party: | Taiho Oncology, Inc. |
ClinicalTrials.gov Identifier: | NCT04507503 |
Other Study ID Numbers: |
TAS-120-401 |
First Posted: | August 11, 2020 Key Record Dates |
Last Update Posted: | February 23, 2024 |
Last Verified: | February 2024 |
Cholangiocarcinoma CCA FGFR2 Gene Rearrangements TAS-120 Futibatinib |
Cholangiocarcinoma Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Futibatinib Antineoplastic Agents |